🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 27 of 116

  1. robot-assisted surgery

    Hospital Authority, Hong Kong

    Rectal Cancer

    phase 3 other active

    1 trial

  2. serplulimab、bevacizumab

    Changhai Hospital

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  3. six courses of zanubrutinib, rituximab and lenalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diffuse Large B-Cell Lymphoma

    phase 3 small molecule active

    1 trial

  4. sunitinib malate

    Pfizer

    Carcinoma, Hepatocellular

    phase 3 small molecule terminated

    1 trial

  5. talazoparib plus enzalutamide

    Pfizer

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. tissue-of-origin (ORIGIN-PanCA○R) profiling

    Fudan University

    Cancer of Unknown Primary Site

    phase 3 gene therapy completed

    1 trial

  7. toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  8. trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 mab active

    1 trial

  9. trifluridine/tipiracil

    Takeda

    Metastatic Oesogastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  10. trofosfamide, idarubicin, etoposide

    Solid Biosciences

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial

  11. venetoclax

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial

  12. vinflunine

    Pierre Fabre Medicament

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  13. volrustomig

    AstraZeneca

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  14. volrustomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Mycofit, 250 mg, kapsułki twarde, Remsima 100 mg powder for concentrate for solution for infusion

    AstraZeneca AB

    Metastatic Non-Small Cell Lung Cancer (mNSCLC)

    phase 3 small molecule active

    1 trial

  15. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial

  16. zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  17. zongertinib

    Boehringer Ingelheim

    Lung Cancer, Non-squamous, Non-small Cell

    phase 3 small molecule active

    1 trial

  18. ​Placebo to Osimertinib - Film-coated tablet - 40mg / 80mg, CARBOPLATIN, TAGRISSO 80 mg film-coated tablets, CISPLATIN, PEMETREXED, PEMETREXED, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. (Z)-endoxifen

    ATOSSA THERAPEUTICS, INC.

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  20. -

    Ningbo Cancer Hospital

    Unresectable intrahepatic cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  21. -

    Talion

    Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

    phase 2 small molecule active

    1 trial

  22. -

    Disc Medicine

    Intrahepatic cholangiocarcinoma (iCCA)

    phase 2 small molecule active

    1 trial

  23. -, -, -, MK-1200, -, -

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  24. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  25. -, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  26. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  28. -, PREDNISONE, PARACETAMOL , FLUDROCORTISONE , ABIRATERONE , -, HYDROCORTISONE, -, Ifinatamab Deruxtecan, -, -, HYDROCORTISONE, HYDROCORTISONE, Opevesostat, DOCETAXEL , ENZALUTAMIDE , PREDNISOLONE

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  29. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

  30. -, Raludotatug Deruxtecan, MK-4830, MK-1308A, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib, Lenvatinib, MK-4280A, DEXAMETHASONE , APREPITANT

    Merck Sharp and Dohme

    Participants with extensive-stage small cell lung cancer

    phase 2 small molecule active

    1 trial

  31. 1-(3-(fluoro-18F)benzyl)guanidine ([18F]mFBG)

    Disc Medicine

    Pheochromocytoma – endocrine adrenal tumor

    phase 2 small molecule active

    1 trial

  32. 12.5mg sunitinib with Cisplatin and Gemcitabine

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  33. 177Lu girentuximab

    Telix Innovations

    Advanced Cancer

    phase 2 small molecule active

    1 trial

  34. 177Lu-DOTA-EB-FAPI radionuclide therapy

    The First People's Hospital of Lianyungang

    Refractory Solid Tumor

    phase 2 small molecule completed

    1 trial

  35. 177Lu-DOTA-TLX591

    Telix Innovations

    Prostate Cancer

    phase 2 mab completed

    1 trial

  36. 177Lu-J591

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  37. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    Oligometastatic prostate carcinoma

    phase 2 small molecule active

    1 trial

  38. 177Lu-PSMA-617

    United Therapeutics Europe Ltd

    Metastatic Hormone Naive Prostate Cancer

    phase 2 small molecule active

    1 trial

  39. 2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer Stage IVA

    phase 2 other active

    1 trial

  40. 2-deoxyglucose

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  41. 225Ac-J591

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 2 small molecule active

    2 trials

  42. 225Ac-LNC1011

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  43. 2X-121

    Allarity Therapeutics

    Advanced Ovarian Cancer

    phase 2 small molecule active

    1 trial

  44. 5-FU medac 50 mg/ml, Injektionslösung, ELVN-002, BENDAFOLIN 10 mg/ml Injektionslösung, ELVN-002, ELVN-002, ELVN-002, ELVN-002, Benda-5 FU 50 mg/ml Injektionslösung, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, ELVN-002, Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, HALAVEN 0.44 mg/ml solution for injection, Capecitabin "Zentiva", filmovertrukne tabletter, ELVN-002, Herceptin 150 mg powder for concentrate for solution for infusion, Capecitabine Ac

    Enliven Therapeutics

    Solid Tumors, Colorectal Cancer and Breast Cancer

    phase 2 small molecule active

    1 trial

  45. 5-Fluorouracil

    Hospital Authority, Hong Kong

    Cancer (Advanced Stage)

    phase 2 small molecule active

    1 trial

  46. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial

  47. 609A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Sarcoma, Soft Tissue

    phase 2 small molecule active

    1 trial

  48. 68Ga-DOTATATE and 68Ga-FAPI

    The First People's Hospital of Lianyungang

    Tumor Positron-Emission Tomography

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.